What's new

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Mar 17, 2025 - 17:11
 0
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Skilarence, dimethyl f...

Next Article

Expo West: Plant Press Pushes Forward, Humm Flexes Formats

Related Posts

Human medicines European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan), clopidogrel,acetylsalicylic acid, Date of authorisation: 09/01/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0

Orphan designation: Arsenic trioxide Treatment of acute promyelocytic leukaemia, 13/12/2024 Positive

Orphan designation: Arsenic trioxide Treatment of acute...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Sitagliptin SUN, sitagliptin fumarate, Date of authorisation: 09/12/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 26, 2025  0